Neurocognitive function and schizophrenia-proneness in individuals dependent on ketamine, on high potency cannabis (skunk) or on cocaine

Pharmacopsychiatry

Volumn 45, Issue 7, 2012, Pages 269-274

  Morgan, C J A ^a   Duffin, S ^a   Hunt, S ^a   Monaghan, L ^a   Mason, O ^a   Curran, H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cannabis; cocaine; dependence; ketamine; prodrome; schizophrenia

Indexed keywords

CANNABIS; COCAINE; KETAMINE; PSYCHOTROPIC AGENT;

ARTICLE; ATTENTION DISTURBANCE; COGNITION; COGNITIVE DEFECT; DISEASE PREDISPOSITION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTIPLE DRUG ABUSE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ATTENTION; CASE-CONTROL STUDIES; COCAINE-RELATED DISORDERS; COGNITION DISORDERS; FEMALE; HUMANS; KETAMINE; MALE; MARIJUANA ABUSE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SCHIZOPHRENIA; SELF REPORT; SUBSTANCE-RELATED DISORDERS;

EID: 84869499270     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0032-1306310     Document Type: Article

References (39)

1. Cannon T. D., Cadenhead K., Cornblatt B. et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry: 2008; 65 28 37
2. Miettunen J., Tormanen S., Murray G. K. et al. Association of cannabis use with prodromal symptoms of psychosis in adolescence. Br J Psychiatry: 2008; 192 470 471
3. Kristensen K., Cadenhead K. S. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res: 2007; 151 151 154
4. Rosen J. L., Miller T. J., DAndrea J. T. et al. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res: 2006; 85 124 131
5. Wylie A. S., Scott R. T., Burnett S. J. Psychosis due to "skunko" BMJ: 1995; 311 125
6. DSouza D. C., Perry E., MacDougall L. et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology: 2004; 29 1558 1572
7. Brady K. T., Lydiard R. B., Malcolm R. et al. Cocaine-induced psychosis. J Clin Psychiatry: 1991; 52 509 512
8. Bartlett E., Hallin A., Chapman B. et al. Selective sensitization to the psychosis-inducing effects of cocaine: a possible marker for addiction relapse vulnerability? Neuropsychopharmacology: 1997; 16 77 82
9. Manschreck T. C., Laughery J. A., Weisstein C. C. et al. Characteristics of freebase cocaine psychosis. Yale J Biol Med: 1988; 61 115 122
10. Allen R. M., Young S. J. Phencyclidine induced psychosis. Am J Psychiatry: 1978; 135 1081 1084
11. Krystal J. H., Karper L. P., Seibyl J. P. et al. Subanesthetic effects of the non-competitive NMDA-antagonist, ketamine, in humans. Arch Gen Psychiatry: 1994; 51 199 214
12. Jentsch J. D., Roth R. H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology: 1999; 30 201 225
13. Morgan C. J., Curran H. V. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl): 2006; 188 408 424
14. McGorry P. D., Killackey E., Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry: 2008; 7 148 156
15. Klosterkotter J., Hellmich M., Steinmeyer E. M. et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry: 2001; 58 158 164
16. Simon A. E., Cattapan-Ludewig K., Zmilacher S. et al. Cognitive functioning in the schizophrenia prodrome. Schizophr Bull: 2007; 33 761 771
17. Pukrop R., Klosterkotter J. Neurocognitive indicators of clinical high-risk states for psychosis: a critical review of the evidence. Neurotox Res: 2010; 18 272 286
18. Solowij N., Hall W., Lee N. Recreational MDMA use in Sydney: a profile of "Ecstasyo" users and their experience with the drug. Br J Addict: 1992; 87 1161 1172
19. Gossop M., Griffiths P., Powis B. et al. Severity of dependence and route of administration of heroin, cocaine and amphetamines. Br J Addict: 1992; 87 1527 1536
20. Wilson B., Cockburn J., Baddeley A. The Rivermead Behavioural Memory Test. Bury St. Edmunds, UK Thames Valley Test Company: 1985
21. Baddeley A., Emslie H., Nimmo-Smith I. The spot the word test: a robust estimate of verbal intelligence based on lexical decision. Br J Clin Psychol: 1993; 32 55 65
22. Beck A. T. The Beck Depression Inventory (BDI). The Psychological Corporation. Harcourt Brace Jovanovitz Inc USA: 1978
23. Spielberger C. State-Trait Anxiety Inventory (Form Y); Palo Alto, California. Mind Garden: 1983
24. Schultze-Lutter F., Addington J., Ruhrmann S. et al. Schizophrenia Proneness Instrument, Adult version (SPI-A).; Roma, Giovanni Fioriti Editore s.r.l.,: 2007
25. Schultze-Lutter F., Steinmeyer E. M., Ruhrmann S. et al. The dimensional structure of self-reported prodromal disturbances in schizophrenia. Clin Neuropsychiatry: 2008; 5 140 150
26. Gross G., Huber G., Klosterkotter J. et al. Bonner Skala für die Beurteilung von Basissymptomen (BSABS; Bonn Scale for the Assessment of Basic Symptoms). Berlin Heidelberg Springer: 1987
27. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev: 2007; 17 347 361
28. Pope H. G. Jr, Gruber A. J., Hudson J. I. et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry: 2001; 58 909 915
29. Honey R. A., Honey G. D., Oloughlin C. et al. Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an FMRI study. Neuropsychopharmacology: 2004; 29 1203 1214
30. Beveridge T. J., Gill K. E., Hanlon C. A. et al. Review. Parallel studies of cocaine-related neural and cognitive impairment in humans and monkeys. Philos Trans R Soc Lond B Biol Sci: 2008; 363 3257 3266
31. Schultze-Lutter F., Klosterkotter J., Picker H. et al. Predicting first episode psychosis by basic symptom criteria. Clin Neuropsychiatry: 2007; 4 11 22
32. Muetzelfeldt L., Kamboj S. K., Rees H. et al. Journey through the K-hole: Phenomenological aspects of ketamine use. Drug Alcohol Depend: 2008; 95 219 229
33. Cornblatt B., Lencz T., Obuchowski M. The schizophrenia prodrome: treatment and high-risk perspectives. Schizophr Res: 2002; 54 177 186
34. Moore T. H., Zammit S., Lingford-Hughes A. et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet: 2007; 370 319 328
35. Zammit S., Allebeck P., Andreasson S. et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ: 2002; 325 1199
36. Hardwick S., King L. A. Home Office Cannabis Potency Study; St Albans. Home Office Scientific Development Branch: 2008
37. Morgan C. J., Rees H., Curran H. V. Attentional bias to incentive stimuli in frequent ketamine users. Psychol Med: 2008; 1 10
38. DSouza D. C. Cannabinoids and psychosis. Int Rev Neurobiol: 2007; 78 289 326
39. McCambridge J., Winstock A., Hunt N. 5-Year trends in use of hallucinogens and other adjunct drugs amongst UK dance drug users. Eur Addict Res: 2007; 13 57 64